Evaluation of Low Molecular Weight Hyaluronic Acid in treatment of supraspinatous Tendinopathy

A Comparison between Low Molecular Weight Hyaluronic Acid (Hyalgan® MW= 500-700 KD) and physioytherapy in supraspinatous Tendinopathy.

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

IRCT

Registry ID

IRCT20150118020702N3

Enrollment

Registered

2020-06-22

Start date

2018-07-23

Completion date

Unknown

Last updated

2020-07-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Supraspinatous thendinopathy. Unspecified rotator cuff tear or rupture, not specified as traumatic

Interventions

Intervention 1: Intervention group1: hyaluronic acid injection performed by physiatrist in tendon.each 2 ml syringe contains hyaluronic acid 20mg. One injection performed with sterility.This drug prod

Eligibility

Sex/Gender

All

Age

No minimum to 65 Years

Inclusion criteria

Inclusion criteria: Adult less than 65 years old with supraspinatous tendinitis Patient with supraspinatous tendinitis who's that between lowermost 6 weeks and uppermost 3 month from initial symptom.

Exclusion criteria

Exclusion criteria: Patient with complete tendon tearing in MRI study Patient had corticosteroid injection less than 3 month ago. Patient with RA, MS, AS, OP, FX, radicular pain of neck and pregnant women.

Design outcomes

Primary

Measure	Time frame
Visual Analogue Scale (VAS Score). Timepoint: Immediately after the injection, one week, one month, and three months after the injection. Method of measurement: The patient answer the question of VAS score questionare in 3 modes of rest,activity,and night 3 times after 1week,after1 month and after 3 months of procesure.;DASH. Timepoint: Immediately after the injection, one week, one month, and three months after the injection. Method of measurement: The patient answer the question of DASH questionare in 3 times after 1week,after1 month and after 3 months of procesure.;Quality of life. Timepoint: Immediately after the injection, one week, one month, and three months after the injection. Method of measurement: The patient answer the questionnare 3 times after 1week,after1 month and after 3 months of procesure.;Range of motion( flextion,extention,medial rotation,lateral rotation,abduction,adduction). Timepoint: Immediately after the injection, one week, one month, and three months after the injection. Method of measurement: Rom of shoulder of patient in each motion measured by goniometer in 1 week,1 month and 3 month after procedure.	—

Measure

Time frame

Visual Analogue Scale (VAS Score). Timepoint: Immediately after the injection, one week, one month, and three months after the injection. Method of measurement: The patient answer the question of VAS score questionare in 3 modes of rest,activity,and night 3 times after 1week,after1 month and after 3 months of procesure.;DASH. Timepoint: Immediately after the injection, one week, one month, and three months after the injection. Method of measurement: The patient answer the question of DASH questionare in 3 times after 1week,after1 month and after 3 months of procesure.;Quality of life. Timepoint: Immediately after the injection, one week, one month, and three months after the injection. Method of measurement: The patient answer the questionnare 3 times after 1week,after1 month and after 3 months of procesure.;Range of motion( flextion,extention,medial rotation,lateral rotation,abduction,adduction). Timepoint: Immediately after the injection, one week, one month, and three months after the injection. Method of measurement: Rom of shoulder of patient in each motion measured by goniometer in 1 week,1 month and 3 month after procedure.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactMansoure Rousta

Artesh University of Medical Sciences

m.rousta1991@gmail.com+98 21 8601 3867

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026